Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial.

BACKGROUND Grass pollen immunotherapy significantly reduces hay fever symptoms and medication requirements. Effects on seasonal asthma are less clear, and concerns over safety persist. OBJECTIVE The goal of this study was to assess the effects of grass pollen immunotherapy on symptoms, bronchial hyperresponsiveness, and quality of life in seasonal rhinitis and asthma. METHODS Forty-four patients with severe summer hay fever (of whom 36 reported seasonal chest symptoms and 28 had seasonal bronchial hyperresponsiveness) participated in a randomized, double-blind, placebo-controlled, parallel group study. After symptom monitoring for one summer, participants received injections of a depot grass pollen vaccine (n = 22) or matched placebo injections (n = 22) in a rapid updosing cluster regimen for 4 weeks, followed by monthly injections for 2 years. Outcome measures included hay fever symptoms and medication use, health-related quality of life, and measurements of nonspecific bronchial responsiveness. RESULTS Significant reductions were observed in the immunotherapy group compared with the placebo group in hay fever symptoms (49%, 15%; P =.01), medication scores (80%, 18%; P =.007), and seasonal chest symptoms (90%, 11%; P <.05). Impairment of overall quality of life (mean score of 7 domains) during the pollen season was less in the immunotherapy group than in the placebo group (median difference [95% CI], 0.8 [0.18-1.5]; P =.02). During the pollen season there was no change in airway methacholine PC(20) (provocation concentration producing a 20% fall in FEV(1)) in the immunotherapy-treated group (P =.5), compared with an almost 3 doubling-dose decrease in the placebo-treated group (P =.01, between-group difference). There were no significant local or systemic side effects during the study. CONCLUSION Grass pollen immunotherapy improves quality of life in seasonal allergic rhinitis and reduces seasonal asthma symptoms and bronchial hyperresponsiveness.

[1]  R. Puy,et al.  Immunotherapy in asthma: an updated systematic review , 1999, Allergy.

[2]  S. Durham,et al.  Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.

[3]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[4]  J. Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997. , 1998, Allergy.

[5]  E. Valovirta.  Capacity of specific immunotherapy in prevention of allergic asthma in children: the Preventive Allergy Treatment Study (PAT). , 1997, Journal of investigational allergology & clinical immunology.

[6]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. , 1997, The Journal of allergy and clinical immunology.

[7]  J. Tonascia,et al.  A controlled trial of immunotherapy for asthma in allergic children. , 1997, The New England journal of medicine.

[8]  R. Davies,et al.  Airway response of asthmatic subjects to inhaled allergen after exposure to pollutants. , 1996, Thorax.

[9]  W. Busse,et al.  Ragweed immunotherapy in adult asthma. , 1996, The New England journal of medicine.

[10]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. , 1996 .

[11]  M. Jacobson,et al.  Grass pollen immunotherapy: efficacy and safety during a 4‐year follow‐up study , 1995, Allergy.

[12]  S. Durham,et al.  Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. , 1991, BMJ.

[13]  G. Guyatt,et al.  Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  H. Mosbech,et al.  Does the effect of immunotherapy last after termination of treatment? , 1988, Allergy.

[15]  G. Nilsson,et al.  Biological equilibration of allergen preparations: methodological aspects and reproducibility , 1987, Clinical allergy.

[16]  J. Bousquet,et al.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. , 1987, The Journal of allergy and clinical immunology.

[17]  Kevin McConway,et al.  Distribution-free methods , 1987 .

[18]  D. Marsh,et al.  The international collaborative study establishing the first international standard for timothy (Phleum pratense) grass pollen allergenic extract. , 1985, The Journal of allergy and clinical immunology.

[19]  O. Østerballe.  Nasal and Skin Sensitivity during Immunotherapy with Two Major Allergens 19, 25 and Partially Purified Extract of Timothy Grass Pollen , 1982 .

[20]  E. Juniper,et al.  Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. , 1981, Thorax.

[21]  H. Løwenstein,et al.  Immunotherapy in Hay Fever with Two Major Allergens 19, 25 and Partially Purified Extract of Timothy Grass Pollen , 1980, Allergy.

[22]  E. Hey,et al.  CONTROLLED TRIAL OF HYPOSENSITISATION TO DERMATOPHAGOIDES PTERONYSSINUS IN CHILDREN WITH ASTHMA , 1978, The Lancet.

[23]  T. A. Ryan,et al.  Algorithm 516: An Algorithm for Obtaining Confidence Intervals and Point Estimates Based on Ranks in the Two-Sample Location Problem [G1] , 1977, TOMS.